IPA unit Talem pens multi-target research deal with Pierre Fabre

Canada-based ImmunoPrecise Antibodies (TSX Venture: IPA) and French drugmaker Pierre Fabre today announced that IPA's subsidiary, Talem Therapeutics and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets.

This strategic collaboration is expected to help expand Talem's portfolio of novel antibodies across oncology. It adds to the variety of diverse relationships that the IPA group of companies holds across the pharmaceutical and biotechnology sector.

Under the research collaboration, scientists from both companies will work together and contribute their respective resources to discover and develop novel antibodies leveraging the IPA group's antibody discovery technologies, such as B cell Select or Deep Display using Timber Pharmaceuticals wild-type and/or transgenic animals, available human libraries, as well as its signature "end-to-end" services.